Outcomes were significantly improved with adjuvant exemestane versus tamoxifen in hormone-receptor–positive patients treated with ovarian function suppression.
Premenopausal women with early-stage, hormone-receptor–positive breast cancer will receive a recommendation of tamoxifen for at least 5 years and as long as 10 years. But whether adding ovarian function suppression (OFS) to tamoxifen or using an aromatase inhibitor (AI) with OFS offers an advantage in terms of recurrence or survival in this patient population has not been defined.
Investigators have now conducted two randomized, phase III trials (TEXT and SOFT) to compare tamoxifen plus OFS versus an AI (exemestane) plus OFS in 4690 premenopausal women with hormone-receptor–positive early breast cancer (median age, 43; 42% with node-positive disease; 57% received adjuvant chemotherapy).
After a median follow-up of 68 months, 5-year disease-fr…
Reviewing Author
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)